It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Peripartum cardiomyopathy (PPCM) is a life-threatening heart failure occurring in the peripartum period. Although mal-angiogenesis, induced by the 16-kDa N-terminal prolactin fragment (16 K PRL), is involved in the pathogenesis, the effect of full-length prolactin (23 K PRL) is poorly understood. We transfected neonate rat cardiomyocytes with plasmids containing 23 K PRL or 16 K PRL in vitro and found that 23 K PRL, but not 16 K PRL, upregulated protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling, and hypoxia promoted this effect. During the perinatal period, cardiomyocyte-specific PERK homogenous knockout (CM-KO) mice showed PPCM phenotypes after consecutive deliveries. Downregulation of PERK or JAK/STAT signaling and upregulation of apoptosis were observed in CM-KO mouse hearts. Moreover, in bromocriptine-treated CM-KO mice, cardiac function did not improve and cardiomyocyte apoptosis was not suppressed during the peripartum period. These results demonstrate that interaction between 23 K PRL and PERK signaling is cardioprotective during the peripartum term.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Tokyo, Isotope Science Center, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); The University of Tokyo Graduate School of Medicine, Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 The University of Tokyo, Isotope Science Center, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
3 The University of Tokyo, Isotope Science Center, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); Tokyo Medical and Dental University, Department of Bioinformational Pharmacology, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130); The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Department of Proteomics, Faculty of Health and Medical Sciences, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
4 The University of Tokyo, Isotope Science Center, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); University of Tsukuba, Laboratory of Laboratory/Sports Medicine, Division of Clinical Medicine, Faculty of Medicine, Tsukuba, Japan (GRID:grid.20515.33) (ISNI:0000 0001 2369 4728)
5 Rhelixa Inc., Tokyo, Japan (GRID:grid.20515.33)
6 The University of Tokyo, Isotope Science Center, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X); Daiichi University of Pharmacy, Center for Supporting Pharmaceutical Education, Fukuoka, Japan (GRID:grid.417740.1) (ISNI:0000 0004 0370 1830)